This activity is supported by an independent education grant from BMS. This online education program has been designed for healthcare professionals globally, excluding the UK.
Join experts Fernando Martinez, MD, and Corey Kershaw, MD, for a case-based exploration of early risk identification in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). This session examines how subtle respiratory symptoms are frequently overlooked, demonstrating how structured risk profiling can prevent diagnostic delays before overt, irreversible lung function loss occurs.
This is Module One of Four. Modules Two, Three, and Four can be found here.
Session Highlights
- Recognize that non-specific symptoms like dry cough and subtle dyspnea represent high-risk flags in RA patients that require prompt investigation.
- Apply the 2023 ACR/CHEST guidelines to conditionally screen at-risk, asymptomatic patients using structured risk assessment tools.
- Evaluate patient risk inputs—including high anti-CCP serology, smoking history, and RA duration—to trigger timely PFT and HRCT referrals.
- Implement cross-specialty collaboration pathways between rheumatology and pulmonology to establish joint checkpoints for early detection.
Target Audience
This activity is intended for pulmonologists, rheumatologists, thoracic radiologists, pathologists, pulmonology nurse practitioners, and physician assistants/associates who are central to the diagnosis and management of IPF and PPF. It is also designed for general practitioners, respiratory therapists, pharmacists, and other multidisciplinary healthcare professionals involved in the care of patients with pulmonary fibrosis.
Faculty
Dr Fernando Martinez is a Professor in the Division of Pulmonary Medicine and Interim Chair of the Department of Medicine at the University of Massachusetts Chan Medical School in Worcester, Massachusetts. Holding an MD and MS, he is a leading clinician and researcher with a long-standing commitment to academic medicine, patient care, and multidisciplinary strategies in respiratory medicine.
Dr Corey Kershaw is a Professor in the Department of Internal Medicine within the Division of Pulmonary and Critical Care Medicine at UT Southwestern. He serves as the Clinical Services Chief for the Division of Pulmonary and Critical Care Medicine, as well as the Medical Director of the Medical Intensive Care Unit and Respiratory Therapy at William P. Clements Jr. University Hospital. He has extensive clinical expertise in managing complex pulmonary conditions and critical care medicine.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr Fernando Martinez, faculty for this educational activity, has the following relevant financial relationships: Advisor for Lung Therapeutics; Consultant, Advisor, and Speaker for Boehringer Ingelheim and Chiesi; DSMB for Pliant; Researcher for AstraZeneca, Bristol Myers Squibb, Chiesi, DevPro, and Vicore.
Dr Corey Kershaw, faculty for this educational activity, has the following relevant financial relationships: Consultant, Advisor, and Speaker for Boehringer Ingelheim; Researcher for Avalyn Pharma, Bristol Myers Squibb, Daewoong Pharmaceutical, PureTech Health/Celea Therapeutics, and United Therapeutics.
The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-26-361-H01-P
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 30, 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 1 November 2026 through to 30 September 2027.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.
This continuing education activity is active starting 1 November, 2026 and will expire on 30 September, 2027.
Estimated time to complete this activity: 15 Minutes